论文部分内容阅读
目的:评价紫杉类药物对晚期乳腺癌患者的临床疗效。方法:选取2013年3月—2015年3月间收治的乳腺癌晚期患者128例,将其分为观察组和对照组,每组64例;对照组患者均给予常规化疗方法治疗,观察组患者在对照组职基础上再给予紫杉类药物治疗;比较两组患者治疗后的总有效率和不良反应的发生率。结果:观察组患者治疗后的总有效率为96.88%高于对照组为85.94%(P<0.05),不良反应的发生率为9.37%低于对照组为20.31%(P<0.05)。结论:采用紫杉类药物与化疗药物联用疗法治疗晚期乳腺癌患者的临床疗效较为显著,不良反应较低。
Objective: To evaluate the clinical efficacy of taxanes in patients with advanced breast cancer. Methods: A total of 128 patients with advanced breast cancer who were admitted to our hospital from March 2013 to March 2015 were divided into observation group and control group, with 64 cases in each group. Patients in the control group were treated by conventional chemotherapy. Patients in observation group Taxus drugs were given on the basis of control group, and the total effective rate and incidence of adverse reactions after treatment were compared between the two groups. Results: The total effective rate of the observation group after treatment was 96.88% higher than that of the control group (85.94%, P <0.05). The incidence of adverse reactions was 9.37%, which was lower than that of the control group (20.31%, P <0.05). Conclusion: The clinical efficacy of the combination therapy of taxanes and chemotherapy drugs in patients with advanced breast cancer is more significant and the adverse reaction is lower.